Get the Latest Crispr Stock Quote and Market Analysis

To get the latest CRISPR stock quote, you can check the NASDAQ website, where CRISPR Therapeutics is listed under the ticker symbol CRSP. They list the current stock price and provide a 52-week chart to track its performance.

CRISPR Therapeutics is a biotechnology company that uses the CRISPR gene editing technology to develop treatments for genetic diseases. It's a key player in the CRISPR market.

The company's stock price can fluctuate based on various market and economic factors, including the success of its clinical trials and partnerships with other companies. This can impact the overall value of the company and its stock price.

For the most up-to-date information, you can also check financial news websites or apps that provide real-time stock quotes and analysis.

The performance of Crispr Therapeutics AG's stock is a crucial aspect to consider when deciding whether to invest in the company. Its current market value is $3,572,044,000.

The stock has traded in a range of $36 to $91 over the past year, with a current price of $41.81. This represents a significant drop from its 52-week high of $91.10.

Here's a breakdown of the stock's performance over different periods:

The stock's beta is 1.67, indicating that it is more volatile than the overall market. The 1-month change is 4.47%, while the 3-month change is -12.77%.

It's essential to consider these performance metrics when evaluating Crispr Therapeutics AG as a potential investment opportunity.

CRISPR Therapeutics is a biotechnology company that focuses on developing gene editing therapies. The company is headquartered in Basel, Switzerland.

CRISPR Therapeutics was founded in 2014 by Rodger Novak, Samarth Kulkarni, and Philipp Schettek. The company's name is an abbreviation of "Clustered Regularly Interspaced Short Palindromic Repeats", which refers to the CRISPR-Cas9 gene editing tool.

CRISPR Therapeutics has a strong presence in the gene editing space, with a pipeline of several promising therapies in development.

We're a company that's been around for over 10 years, with a mission to provide top-notch services to our clients. Our team is comprised of experienced professionals who are passionate about what they do.

We have a strong presence in the industry, with a client base that spans across multiple sectors. Our services are designed to meet the unique needs of each client, and we take pride in our ability to deliver results.

We're committed to staying ahead of the curve, with ongoing training and development programs for our staff. This ensures that our team is equipped with the latest knowledge and skills to tackle even the toughest challenges.

Our company culture is built on a foundation of teamwork, innovation, and customer satisfaction. We believe in fostering a positive and supportive work environment that encourages collaboration and creativity.

We're proud of our achievements and the impact we've made in the industry. Our clients appreciate our dedication to excellence and our commitment to delivering high-quality services.

As we dive into the company information of CRISPR Therapeutics, let's take a closer look at who owns the company. The largest shareholder is actually the freefloat, holding a whopping 95.70% of the shares.

The largest institutional shareholder is ARK Investment Management LLC, with a 10.69% stake in the company. This is a significant holding, indicating that ARK Investment Management LLC has a substantial influence on the company's decisions.

Another notable institutional shareholder is Capital Research & Management Co. (International Investors), which holds a 9.64% stake in CRISPR Therapeutics. This is a significant holding, and it's not surprising that Capital Research & Management Co. (International Investors) is a major player in the company's ownership structure.

Here's a list of the top shareholders in CRISPR Therapeutics, ranked by their percentage of ownership:

It's interesting to note that the largest shareholders are primarily institutional investors, indicating that the company is likely to be influenced by the decisions of these large investors.